According to a recent LinkedIn post from Neuromod Devices Ltd, company representatives will be present at the DSOHH conference in Nyborg Strand, Denmark, on April 16–17 to discuss its Lenire tinnitus treatment technology. The post notes that Lenire will be featured at Booth 23, with conversations encouraged around clinical outcomes, patient experiences, and potential collaborations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests Neuromod is prioritizing direct engagement with ENT and audiology professionals in a regional specialist setting, which may support clinician adoption and prescription volume over time. For investors, visibility at focused industry meetings like DSOHH could help validate the bimodal neuromodulation approach, deepen referral networks, and potentially strengthen the company’s competitive position in tinnitus care if such outreach translates into sustained clinical uptake and reimbursement traction.